The CGuard Prime TransCarotid Stent System, when used in conjunction with an embolic protection system specified in the labeling, is indicated for improving carotid luminal diameter in patients at high risk for adverse events from carotid endarterectomy who require carotid revascularization and meet the criteria outlined below:
Compatible Embolic Protection Systems: ENROUTE™ Transcarotid Neuroprotection System.
ENROUTE™ is a registered trademark of Boston Scientific Corporation.
* Among commercially available carotid stents. Data on file.
** Defense is defined as the absence of restenosis
† Myocardial Infarction
‡ Based on modified intent-to-treat Kaplan-Meier analysis
CGuard® is CE MDR Approved
CGuard® has not received approval from the U.S. Food and Drug Administration (FDA) for commercial use in the United States.
The CGuard® EPS is indicated for improving carotid luminal diameter in patients at high risk for adverse events from carotid endarterectomy who require carotid revascularization and meet both criteria outlined below:
The following accessories are compatible with the CGuard® Embolic Prevention System:
CGuard® and the InspireMD Logo are registered trademarks of InspireMD, Inc.
Abbott® and Emboshield NAV6™ are registered trademarks of Abbott Laboratories.
Medtronic® and Mo.Ma™ are registered trademarks of Medtronic Corporation.